Literature DB >> 19863448

Bone marrow findings at diagnosis in patients with multisystem langerhans cell histiocytosis.

Maria Laura Galluzzo1, Jorge Braier, Sergio D Rosenzweig, Maria T Garcia de Dávila, Diego Rosso.   

Abstract

This study was designed to describe the bone marrow features of multisystem Langerhans cell histiocytosis (LCH) at diagnosis in patients with or without hematologic dysfunction. A retrospective review of bone marrow biopsies from patients with multisystem LCH was performed. Cases were diagnosed at the Garrahan Hospital between 1987 and 2004. Routine and immunohistochemistry techniques (hematoxylin-eosin, periodic acid-Schiff, Giemsa, Gomori reticulin, and CD1a, CD68, and CD61) were evaluated. Clinical outcome and laboratory data were obtained from the medical charts. Twenty-two bone marrow biopsies from patients with multisystem LCH were reviewed at onset of disease. Four patients had no hematologic dysfunction and the other 18 patients had monocytopenia (9), bicytopenia (7), or tricytopenia (2). Increased number and dysplasia of megakaryocytes were evident in 22/22 samples and emperipolesis was present in 21/22 (95%). Aggregates of histiocytes and hemophagocytosis were seen in 9/22 samples. Myelofibrosis was found in 16/17 (94%) evaluable samples at diagnosis. No association of myelofibrosis and cytopenias or clinical outcome was found. Positive CD1a confirmed the presence of LCH cells in 3/22 (14%) samples. Hemophagocytosis and poor outcome were significantly more common in patients with bilineage and trilineage cytopenias. Langerhans cell histiocytosis cells were rarely seen in the bone marrow of these patients (14%); increased histiocytes and hemophagocytosis were more commonly found (41%). Hemophagocytosis was associated with severe cytopenias. Bicytopenia and tricytopenia were associated with poor outcome (death). Myelofibrosis, megakaryocytic dysplasia, and emperipolesis were common findings.

Entities:  

Mesh:

Year:  2010        PMID: 19863448      PMCID: PMC3740343          DOI: 10.2350/09-05-0651-OA.1

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  24 in total

1.  Histiocytosis x--an analysis of prognostic factors.

Authors:  E Lahey
Journal:  J Pediatr       Date:  1975-08       Impact factor: 4.406

2.  Ultrastructure of bone marrow tissue in so-called primary (idiopathic) myelofibrosis-osteomyelosclerosis (agnogenic myeloid metaplasia). I. Abnormalities of megakaryopoiesis and thrombocytes.

Authors:  J Thiele; T Kuemmel; C Sander; R Fischer
Journal:  J Submicrosc Cytol Pathol       Date:  1991-01

3.  The frequency and significance of megakaryocytic emperipolesis in myeloproliferative and reactive states.

Authors:  A W Cashell; D H Buss
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

4.  Quantitation of bone marrow reticulin--a normal range.

Authors:  D E Bauermeister
Journal:  Am J Clin Pathol       Date:  1971-07       Impact factor: 2.493

5.  Disseminated histiocytosis X: analysis of prognostic factors based on a retrospective study of 50 cases.

Authors:  C Nezelof; F Frileux-Herbet; J Cronier-Sachot
Journal:  Cancer       Date:  1979-11       Impact factor: 6.860

6.  Bone marrow involvement in histiocytosis X.

Authors:  K McClain; N K Ramsay; L Robison; R D Sundberg; M Nesbit
Journal:  Med Pediatr Oncol       Date:  1983

7.  Histo- and immunomorphometry of megakaryopoiesis in chronic myeloid leukemia with myelofibrosis and so-called primary (idiopathic) osteo-myelofibrosis/-sclerosis.

Authors:  J Thiele; T Steinberg; B Hoeppner; S Wienhold; S Wagner; D Dienemann; R Fischer
Journal:  Anal Cell Pathol       Date:  1990-07       Impact factor: 2.916

8.  Myelofibrosis arising in treated histiocytosis X.

Authors:  D J Sartoris; D Resnick
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

9.  [Emperipolesis in megakaryocytes in patients with thrombocytosis in the course of myeloproliferative disorders].

Authors:  R Bobik; M Podolak-Dawidziak; M Kiełbiński; M Jeleń; T Wróbel
Journal:  Acta Haematol Pol       Date:  1995

10.  Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans cell histiocytosis. Clinical Writing Group of the Histiocyte Society.

Authors:  V Broadbent; H Gadner; D M Komp; S Ladisch
Journal:  Med Pediatr Oncol       Date:  1989
View more
  6 in total

1.  Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.

Authors:  Lynn H Lee; Anjelika Gasilina; Jayeeta Roychoudhury; Jason Clark; Francis X McCormack; Joseph Pressey; Michael S Grimley; Robert Lorsbach; Siraj Ali; Mark Bailey; Philip Stephens; Jeffrey S Ross; Vincent A Miller; Nicolas N Nassar; Ashish R Kumar
Journal:  JCI Insight       Date:  2017-02-09

2.  New insights into the molecular pathogenesis of langerhans cell histiocytosis.

Authors:  Francesca M Rizzo; Mauro Cives; Valeria Simone; Franco Silvestris
Journal:  Oncologist       Date:  2014-01-16

3.  Concurrent Mastoid Cellulitis and Langerhans Cells Histiocytosis: 
A Challenging Diagnosis.

Authors:  Hui Yan Ong; Liang Chye Goh; Kalimuthu Santhi; Mohamad Mokhtar Sha'ariyah
Journal:  Oman Med J       Date:  2018-03

4.  Clinical and magnetic resonance imaging feature differences between solitary and multiple type Langerhans cell histiocytosis involving the craniofacial bone.

Authors:  Shu Matsushita; Taro Shimono; Tomohisa Okuma; Takeshi Inoue; Takao Manabe; Yukio Miki
Journal:  Heliyon       Date:  2022-01-11

5.  BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis.

Authors:  Ko Kudo; Tsutomu Toki; Rika Kanezaki; Tatsuhiko Tanaka; Takuya Kamio; Tomohiko Sato; Shinya Sasaki; Masaru Imamura; Chihaya Imai; Kumiko Ando; Harumi Kakuda; Takehiko Doi; Hiroshi Kawaguchi; Masahiro Irie; Yoji Sasahara; Akihiro Tamura; Daiichiro Hasegawa; Yosuke Itakura; Kenichiro Watanabe; Kenichi Sakamoto; Yoko Shioda; Motohiro Kato; Kazuko Kudo; Reiji Fukano; Atsushi Sato; Hiroshi Yagasaki; Hirokazu Kanegane; Itaru Kato; Katsutsugu Umeda; Souichi Adachi; Tatsuki Kataoka; Akira Kurose; Atsuko Nakazawa; Kiminori Terui; Etsuro Ito
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

6.  Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years.

Authors:  Riccardo Haupt; Milen Minkov; Itziar Astigarraga; Eva Schäfer; Vasanta Nanduri; Rima Jubran; R Maarten Egeler; Gritta Janka; Dragan Micic; Carlos Rodriguez-Galindo; Stefaan Van Gool; Johannes Visser; Sheila Weitzman; Jean Donadieu
Journal:  Pediatr Blood Cancer       Date:  2012-10-25       Impact factor: 3.167

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.